The Bob Harrington Show

What is the incidence of post-COVID myocarditis and when is it safe to return to play? Bob Harrington and Manesh Patel discuss our evolving understanding of how SARS-CoV-2 effects the hearts of athletes and weekend warriors. To read a transcript or to comment https://www.medscape.com/author/bob-harrington Early Studies Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19) https://doi.org/10.1001/jamacardio.2020.3557 Cardiovascular Magnetic Resonance Findings in Competitive Athletes Recovering From COVID-19 Infection https://doi.org/10.1001/jamacardio.2020.4916 Pooled autopsy https://www.medscape.com/viewarticle/944496 Pathological Evidence for SARS-CoV-2 as a Cause of Myocarditis: JACC Review Topic of the Week https://doi.org/10.1016/j.jacc.2020.11.031 Lake Louise Criteria https://pubmed.ncbi.nlm.nih.gov/30545455/ Recognition and Initial Management of Fulminant Myocarditis A Scientific Statement From the American Heart Association https:/

Bob Harrington and Mike Gibson continue their review of 2020, discussing the 'riddle wrapped in an enigma' that was the COVID-19 pandemic.

The annual tradition continues as did cardiology research despite a pandemic. Trials on fish oils, statins, SGLT2 inhibitors, and antiplatelets are among the selections of Drs Harrington and Gibson.

Three editors of cardiology journals -- Drs Harrington, Yancy, and Nallamothu -- discuss the challenges of maintaining quality during the COVID-19 surge in submissions.

Hematologist Mary Cushman discusses arterial and venous thrombosis issues with SARS-CoV-2 and the role of anticoagulation.

Bob Harrington asks Michelle Albert why mortality rates are so high in minority communities, and whether COVID-19 will lead to meaningful changes in health and social inequities.

'They fancy themselves free. And no one will ever be free so long as there are pestilences,' wrote Camus in 'The Plague', which Abraham Verghese sees as relevant to our collective experience of COVID-19.

Cardiologist Lisa Rosenbaum seeks meaning in her work as a physician and correspondent for the New England Journal of Medicine, a quest first started by her grandfather who was also a physician-writer.

Bob Harrington and Mike Gibson continue their review of 2019 with the 'hottest trial of the year' and what to expect in healthcare in 2020.

'It's like we're in the '90s again.' Drs Gibson and Harrington review top cardiology trials on revascularization, lipid management, and antithrombotics in part 1 of their annual wrap-up.

A family history of sudden death was the impetus for author Sandeep Juahar's fascination with the heart, which led to a career in cardiology and his latest book Heart: A History.

Fewer black men are going into medicine today than in 1978. Drs Harrington and Capers discuss how to increase diversity in medicine and why it's important for caregivers to reflect the population they treat.

Optimal medical therapy and recent advances show that heart failure is preventable and not obligatory, Clyde Yancy tells Bob Harrington.

It's not all dire. Tait Shanafelt, MD, is witnessing improvement and momentum in the field of clinician wellness. Learn about his journey from hematology to chief wellness officer.

Volunteering at a VA hospital was the first step in biostatistician Frank Harrell's illustrious career in cardiovascular research.

Despite the vastness of available data, don't forget the basics, warns biostatistician Frank Harrell in this conversation with Bob Harrington.

Drs Harrington and Yeh discuss the pros, cons, and cautions of using Twitter in the cardiovascular community.

Drs Harrington and Joynt Maddox discuss the move from volume-based to performance-based payment models and how to develop evidence-based quality metrics that make clinical sense.

Drs Harrington and Gibson discuss burning issues in medicine, including artificial intelligence, social media, wearable tech, and the new hypertension guidelines.

Trials on PCSK9 inhibitors, antiplatelets, anticoagulants, and even catheter ablation of atrial fibrillation are among Drs Harrington and Gibson's picks for what to look for in 2018.